SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Gwen Ifill — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientGwen Ifill
Date of birth1955-09-29
IdentifiersMRN HR-ML032-SYN-TD; SSN (made up) 000-32-5814
Document date2016-08-11
AuthorLorna Achebe-Price, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Ms. Ifill is a 60-year-old journalist with stage IIIC2 mismatch repair deficient endometrial cancer, treated with surgery and six cycles of dostarlimab, carboplatin and paclitaxel, who comes for her yearly preventive visit six weeks after the end of combination treatment. The CT then showed no evidence of disease. She had her first maintenance dose of dostarlimab six weeks ago and has her second today. Since starting levothyroxine her energy has improved and she no longer feels cold. The tingling in her toes is slowly fading. She has had no vaginal bleeding or discharge, pelvic pain, cough, leg swelling or weight loss. She is working full days again, covering the election campaign, and walks most mornings. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 60
Endometrial cancerNo evidence of disease at the end of treatment; dostarlimab maintenance dose 2 today
ThyroidLevothyroxine for six weeks; energy better
MoodPHQ-2 0

Health risk assessment. Completed by the patient on the clinic's online form before the visit and reviewed with her by Dr. Achebe-Price. [S]

DomainFinding
Self-rated healthGood, and improving
PsychosocialBusy and engaged at work; close friends and church community; low stress apart from the campaign schedule
Substance useNo tobacco; alcohol occasionally, within low-risk limits; no drug use
Physical activityBrisk walk of 30 minutes on most mornings
NutritionRegular meals; trying to eat more vegetables and less takeout on long workdays
SleepSix to seven hours on work nights
Falls and home safetyNo falls; numbness in the toes is fading; good lighting at home
Sexual healthNot sexually active at present; knows to report vaginal dryness or pain
Activities of daily livingIndependent
Seat belt and smoke alarmsAlways wears a seat belt; smoke alarms tested

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy improving; no fever or weight loss
EyesNegativeNo vision change
Ears, nose, mouth, and throatNegativeNo mouth sores
CardiovascularNegativeNo chest pain, palpitations or leg swelling
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo diarrhea, abdominal pain or blood in the stool
GenitourinaryNegativeNo vaginal bleeding or discharge; no urinary symptoms
BreastNegativeNo lump or nipple change
MusculoskeletalNegativeNo joint pain or swelling
IntegumentaryNegativeNo rash or itching
NeurologicalPositiveFaint tingling in the toes, fading
EndocrineNegativeNo longer feels cold; no thirst
PsychiatricNegativeMood good; PHQ-2 0

13 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2016-02-03 to 2016-02-17completedS
Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2016-02-24 to 2016-06-09completedS
Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2016-02-24 to 2016-06-09completedS
Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2016-02-24 to 2016-06-09completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2016-02-24 to 2016-06-30completedS
Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three yearsEvery 6 weeksIntravenous route2016-06-30activeS
Levothyroxine 75 mcg oral tablet, one tablet daily before breakfastOne tablet daily before breakfastOral route2016-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2016-08-11Body height165cmS
2016-08-11Body weight73kgS
2016-08-11Body mass index (BMI) [Ratio]26.8kg/m2S
2016-08-11Systolic blood pressure124mm[Hg]S
2016-08-11Diastolic blood pressure78mm[Hg]S
2016-08-11Heart rate70/minS
2016-08-11Respiratory rate16/minS
2016-08-11Body temperature36.6CelS
2016-08-11Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2016-08-11Thyrotropin [Units/volume] in Serum or Plasma3.6m[IU]/L0.4-4.5 mIU/LNormalS
2016-08-11Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2016-08-11Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
2016-08-11Glucose [Mass/volume] in Serum or Plasma93mg/dL70-99 mg/dLNormalS
2016-08-11Cholesterol [Mass/volume] in Serum or Plasma204mg/dL<=199 mg/dLHighS
2016-08-11Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation124mg/dL<=129 mg/dLNormalS
2016-08-11Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2016-08-11Triglyceride [Mass/volume] in Serum or Plasma110mg/dL<=149 mg/dLNormalS
2016-08-11Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2016-08-11; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 73.0 kg; blood pressure 124/78; pulse 70
NeckThyroid not enlarged or tender; no lymph nodes
BreastsClinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes
CardiovascularRegular rhythm; no murmur
RespiratoryClear
AbdomenPort-site scars healed; soft, non-tender; no mass
Lymph nodesNo inguinal or supraclavicular nodes
ExtremitiesNo leg swelling; calf circumferences equal
SkinNo rash or suspicious lesions
NeurologicalPinprick slightly reduced over the toes only; vibration and ankle reflexes normal; steady gait
PsychiatricEngaged and direct

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.
Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2013 stage IIIC2iiactiveconfirmed C77.8S — Synthetic nodal disease found at surgical staging.
Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities)activeconfirmed G62.0S — Synthetic common effect of paclitaxel.
Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2)activeconfirmed E03.2S — Synthetic immune-related adverse event, among the most common with PD-1 inhibitors.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today124/78 mmHg
Depression screeningCompleted todayPHQ-2 score 0; PHQ-9 4 six weeks ago
Unhealthy alcohol use screeningCompleted todayOccasional use within low-risk limits
Tobacco useCompleted todayNever
Breast cancer screeningOrderedMammogram every two years from 40 to 74; none in the past two years on file; booked in two weeks
Cervical cancer screeningNot indicatedTotal hysterectomy with removal of the cervix for endometrial cancer; routine vaginal cytology is not recommended for surveillance
Colorectal cancer screeningOrderedNo screening on file; the tumor's MLH1 loss is explained by promoter methylation, so average-risk screening applies; stool immunochemical test chosen, with colonoscopy if positive
Diabetes and lipid screeningCompleted todayA1c 5.5% at intake; total cholesterol 204, LDL 124, HDL 58, triglycerides 110 mg/dL; ten-year risk below the statin threshold
HIV and hepatitis C screeningUp to dateBoth negative before cancer treatment
Osteoporosis screeningNot indicatedAge 60 without a fracture, steroid course or low body weight; bone density at 65
Lung cancer screeningNot indicatedNever smoker
Pneumococcal, zoster and Tdap vaccinesCompleted todayPCV20, recombinant zoster dose 1 and Tdap given today
Influenza and COVID-19 vaccines, this seasonDueThis autumn, when the season's vaccines arrive
Dental and eye examinationsDueDental review and an eye examination advised this year

Immunizations given today: Pneumococcal conjugate vaccine PCV20; Recombinant zoster vaccine, dose 1 of 2; Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) [S]

Guideline basis: Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Breast Cancer: Screening (2024); Cervical Cancer: Screening (2018); Colorectal Cancer: Screening (2021); Osteoporosis to Prevent Fractures: Screening (2025); Adult Immunization Schedule by Age (2026)

Follow-up: Mammogram in two weeks; stool test result by phone. Dostarlimab every six weeks with TSH, free T4, liver tests and glucose. Gynecologic oncology examination every three months and CT every six months. Influenza and COVID-19 vaccines this autumn. Next preventive visit in one year. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment aimed at cure and control of her cancer, wants to be told plainly what is happening, and wants to make her own decisions. She named a health care agent, recorded in the confidential part of the chart and not named here, and asked that information about her health be shared only with the people she names. She chose not to record other treatment preferences today. To be revisited yearly or if her illness changes. [S]